The MOLLI™ Marker is compatible with ultrasound imaging
Marker successfully deployed
Marker deployment in a chicken breast phantom*
*Nicolae, Alexandru, et al. “Evaluation of a ferromagnetic marker technology for intraoperative localization of nonpalpable breast lesions.” American Journal of Roentgenology 212.4 (2019): 727-733.
Imaging in Patient
Superficial breast ultrasonographic image of the MOLLI Marker alongside a radioactive seed implanted in a patient.**
**Data on file at MOLLI Surgical.
The MOLLI™ Marker is compatible with mammographic imaging
Lateral oblique mammographic image of the MOLLI Marker and the radioactive seed implanted in a patient.*
*Dr. Nicole Look Hong, Dr. Frances Wright, Mark Semple, MA Sc; Alexandru Nicolae, MSc; Ananth Ravi, PhD; University of Toronto and Sunnybrook Hospital Odette Cancer Centre. Results of a Phase I, Prospective, Non-randomized Study Evaluating a Magnetic Occult Lesion Instrument (MOLLI) for Excision of Non-palpable Breast Lesions. Poster presented at the 2019 American Society of Breast Surgeons annual meeting, Dallas, Texas. Download the PDF
The MOLLI™ Marker is Magnetic Resonance (MR) conditional
The MOLLI Marker is intended to be placed percutaneously in soft tissue to temporarily mark a surgical site intended for surgical removal.
A patient with an implanted MOLLI Marker can be imaged using a 1.5 T or 3.0 T MR system.
Evidence-based use of MRI in breast cancer
MRI for breast cancer screening, diagnosis, and treatment
- MRI screening indicated for BRCA mutation or at high risk of breast cancer.
- Preoperative MR imaging does not improve surgical outcomes.
- MRI indicated to monitor response during neoadjuvant chemotherapy.